CLRB vs. ICCC, XLO, CELU, ACHL, KZR, TNXP, VYNE, ALVR, ALRN, and NBRV
Should you be buying Cellectar Biosciences stock or one of its competitors? The main competitors of Cellectar Biosciences include ImmuCell (ICCC), Xilio Therapeutics (XLO), Celularity (CELU), Achilles Therapeutics (ACHL), Kezar Life Sciences (KZR), Tonix Pharmaceuticals (TNXP), VYNE Therapeutics (VYNE), AlloVir (ALVR), Aileron Therapeutics (ALRN), and Nabriva Therapeutics (NBRV). These companies are all part of the "pharmaceutical products" industry.
Cellectar Biosciences vs.
Cellectar Biosciences (NASDAQ:CLRB) and ImmuCell (NASDAQ:ICCC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.
In the previous week, ImmuCell had 3 more articles in the media than Cellectar Biosciences. MarketBeat recorded 4 mentions for ImmuCell and 1 mentions for Cellectar Biosciences. Cellectar Biosciences' average media sentiment score of 0.55 beat ImmuCell's score of 0.17 indicating that Cellectar Biosciences is being referred to more favorably in the media.
Cellectar Biosciences received 122 more outperform votes than ImmuCell when rated by MarketBeat users. However, 73.33% of users gave ImmuCell an outperform vote while only 55.35% of users gave Cellectar Biosciences an outperform vote.
16.4% of Cellectar Biosciences shares are owned by institutional investors. Comparatively, 13.5% of ImmuCell shares are owned by institutional investors. 3.7% of Cellectar Biosciences shares are owned by insiders. Comparatively, 6.6% of ImmuCell shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Cellectar Biosciences currently has a consensus price target of $17.67, suggesting a potential upside of 7,009.32%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Cellectar Biosciences is more favorable than ImmuCell.
Cellectar Biosciences has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. Comparatively, ImmuCell has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500.
Cellectar Biosciences has a net margin of 0.00% compared to ImmuCell's net margin of -15.99%. Cellectar Biosciences' return on equity of 0.00% beat ImmuCell's return on equity.
ImmuCell has higher revenue and earnings than Cellectar Biosciences. ImmuCell is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Cellectar Biosciences beats ImmuCell on 10 of the 17 factors compared between the two stocks.
Get Cellectar Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cellectar Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:CLRB) was last updated on 1/21/2025 by MarketBeat.com Staff
